Take Homes in CAR T-cell Therapy

SAN DIEGO — A ketogenic diet may improve antitumor function through beta-hydroxybutyrate, according to early research presented in a plenary scientific session at the ASH Annual Meeting and Exposition.

SAN DIEGO — A new chimeric antigen receptor T-cell therapy option made in less than a day may be a new option for patients with relapsed/refractory non-Hodgkin lymphoma, according to research presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Paolo Caimi, MD, spoke with Healio about research updates on chimeric antigen receptor T-cell therapy presented at ASH Annual Meeting and Exposition.

SAN DIEGO — A treatment regimen of loncastuximab tesirine combined with venetoclax may be safe and effective in a subset of patients with non-Hodgkin lymphoma, according to early research presented at ASH Annual Meeting and Exposition.

In this video, Frederick Locke, MD, co-leader of the Immunology Program at Moffitt Cancer Center discusses three randomized trials testing CD19-directed autologous chimeric antigen receptor T-cell therapies against chemotherapy and autologous transplant in the second line setting for lymphoma, which were presented at ASH.

In this video, Rayne Rouce, MD, discusses the top chimeric antigen receptor T-cell therapy-related presentations at ASH.

In this video, Rayne Rouce, MD, discusses the top chimeric antigen receptor T-cell therapy-related presentations at ASH, including several presentations targeting T-cell malignancies, which she said is exciting.

In this video, Joshua Sasine, MD, PhD, assistant professor of medicine hematology & cellular therapy at the Samuel Oschin Cancer Center Regenerative Medicine Institute, discusses a presentation from his group at ASH on the association between CAR T-cells and the cytopenia that commonly occur after therapy.

In this video, Joshua Sasine, MD, PhD, assistant professor of medicine hematology and cellular therapy at Samuel Oschin Cancer Center Regenerative Medicine Institute, discusses new allogeneic chimeric antigen receptor T-cell therapy data.

In this video, Joshua Sasine, MD, PhD, discusses a set of abstracts presented at ASH that evaluated natural killer cell therapies such as FT596 and FT516 in patients with relapsed/refractory B-cell lymphoma.